Original scientific paper
https://doi.org/10.20471/acc.2024.63.03-04.02
Diagnostic Value of Stimulated Serum Thyroglobulin in the Follow-up of Patients with Differentiated Thyroid Cancer
Vlado Wagenhofer
; Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Osijek, Osijek, Croatia; Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
*
Ivan Mihaljević
; Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Osijek, Osijek, Croatia; Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; Academy of Medical Sciences of Croatia, Croatia
Tatjana Kralj
; Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Osijek, Osijek, Croatia; Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
Dubravka Vrdoljak
; Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Osijek, Osijek, Croatia;
Tomislav Kizivat
; Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Osijek, Osijek, Croatia; Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
* Corresponding author.
Abstract
The aim was to determine the diagnostic value of stimulated serum thyroglobulin
(sTg) for the follow-up of patients with differentiated thyroid cancer (DTC) and to evaluate whether
repeated sTg measurement provides additional clinical benefit in detecting persistent or recurrent structural
disease if the initial sTg was negative. The retrospective study included 388 consecutive patients
with DTC treated and followed-up between 2004 and 2018 at the Clinical Institute of Nuclear Medicine
and Radiation Protection, Osijek University Hospital. The negative predictive value (NPV) of the
first sTg measured 12 months after the initial treatment was compared with NPV of sTg measured
annually during 3 consecutive years of follow-up. The first sTg NPV was 99.5% in the group of lowrisk
patients and 96.1% in the group of intermediate-risk patients. In both low- and intermediate-risk
groups, there were no differences between the first sTg NPV and NPV of sTg measured annually during
3 years of follow-up period. Repeated measurement of the sTg after initially negative result had a limited
clinical value for detecting persistent or recurrent structural disease and cannot be recommended in
routine follow-up of low- and intermediate-risk patients with DTC.
Keywords
Thyroid cancer; Risk assessment; Thyroglobulin
Hrčak ID:
333019
URI
Publication date:
31.12.2024.
Visits: 790 *